Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma: early-phase trial registry
89 of 269 indexed Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #36 of 28,707 conditions by registered trial count.
269 US clinical trials · 89 currently recruiting · #36 of 28,707 conditions by registered trial count
Melanoma: 269 US clinical trials tracked, 89 recruiting.
Melanoma is the subject of 269 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 184 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 20 of these trials.
Enrollment posture brief
Registry condition melanoma
OPEN 89 | RECR 33% | LATE 19 | EARLY 184 | RANK #36 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Melanoma lists 89 open slots (33% of 269 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma is recruiting below its size-band peers.
89 of 269 indexed trials (33.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Melanoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 20 of 269 trials (7.4%). 139 distinct sponsors appear on at least one study for this condition label.
-
Typical Melanoma enrolment sits around 72 participants.
Median target enrolment is 72 among the 267 trials that report a genuine target (sentinel values excluded). 155 of those (58.1%) plan for fewer than 100 participants.
-
Melanoma research is mostly interventional.
231 interventional and 38 observational studies make up this index (85.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
269 total, page 2 of 6
In Vivo Real-time Detection of Circulating Melanoma Cells
University of Arkansas
NCT01776905
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
Boehringer Ingelheim
NCT07224425
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Craig L Slingluff, Jr
NCT05839912
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07115043
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
M.D. Anderson Cancer Center
NCT05053555
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
IO Biotech
NCT05280314
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
NCT06712927
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05859074
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
University of Louisville
NCT01638676
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Obsidian Therapeutics
NCT06060613
Evaluation of Hypoxia in Primary Melanoma
Yana Najjar
NCT06831071
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT04572451
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Replimune
NCT06887348
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
NCT03454035
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics
NCT06566092
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
NCT04038619
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co.
NCT05746897
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06961357
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
M.D. Anderson Cancer Center
NCT06548789
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics
NCT06398418
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
NCT05830058
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT05607095
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co.
NCT04370587
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Dana-Farber Cancer Institute
NCT04930783
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
John Kirkwood
NCT06599619
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Diwakar Davar
NCT05130177
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Yana Najjar
NCT06216938
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
University of Utah
NCT06365619
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04996823
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Duke University
NCT05077137
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
University of Wisconsin, Madison
NCT06199713
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Jordan Kharofa
NCT07225036
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Yana Najjar
NCT04658303
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Loyola University
NCT02870244
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
NCT05264974
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
University of California, Irvine
NCT06771544
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
NCT00582647
A Model for Genetic Susceptibility: Melanoma
Memorial Sloan Kettering Cancer Center
NCT00591500
MElanoma Research Lymph Node Prediction Implementation National_001
SkylineDx
NCT04759781
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals
NCT05608291
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals
NCT05352672
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT00338377
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Merck Sharp & Dohme
NCT05933577
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Merck Sharp & Dohme
NCT03553836
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics
NCT05973487
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Bristol-Myers Squibb
NCT04099251
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Bristol-Myers Squibb
NCT03470922
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 117 |
| Phase 2 | 67 |
| Phase 3 | 16 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma page
269 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Melanoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma condition card totals 269 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.